Asia PacificENPublic drug registration overview
Singapore Pharmaceutical Registration Pathway
Market Overview Market profile: Singapore is a smaller market by volume, but it is highly transparent, Englishfriendly, and important for innovative drugs, generics, biosimilars, a...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: Singapore Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulatory maturity: High. HSA regulates therapeutic product registration, dealer licensing, GMP, variations, pharmacovigilance, and recalls.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Market profile: Singapore is a smaller market by volume, but it is highly transparent, English-friendly, and important for innovative drugs, generics, biosimilars, and Southeast Asia regional headquarters strategy.
- Regulatory maturity: High. HSA regulates therapeutic product registration, dealer licensing, GMP, variations, pharmacovigilance, and recalls.
- Core decision: First confirm whether the product is a Therapeutic Product, then select NDA, GDA, or biosimilar application type and the Full, Abridged, Verification, or other evaluation route.
Regulator
- Authority: Health Sciences Authority (HSA)
- Electronic system: PRISM
- Legal framework: Health Products Act and Health Products (Therapeutic Products) Regulations 2016
Product Types and Review Pathways
| Type | Common application | Key point |
|---|---|---|
| New drug | NDA-1 / NDA-2 / NDA-3 | Full, Abridged, or Verification route depending on overseas approval and dossier status |
| Generic | GDA-1 / GDA-2 | Quality, reference product, BE, and labeling consistency |
| Biosimilar | Biosimilar application | Quality comparability plus nonclinical and clinical bridging |
| POM / P / GSL | Forensic classification | Determines prescription, pharmacy, and general sale access |
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.